▲
STOCKUPSIDE.IO
Analyst Price Target Intelligence
← Full Rankings
← Back to rankings
Ranked #4214 by analyst upside · 2026-09-28
MRNA
Moderna, Inc.
Healthcare · Market Cap $79B · P/E 0x
ANALYST PRICE TARGET
-39.9%
implied upside to consensus target
Current Price $198.88
Consensus Target $119.56
Bull Target $170.0
Bear Target $45.0
Analysts Covering 18
ANALYST CONSENSUS - HOLD
Strong Buy
1
Buy
3
Hold
13
Sell
1
52-Week Low $22.28
52-Week High $202.67
YTD Return +544.5%
FUNDAMENTALS
Market Cap $79B
P/E Ratio (TTM) N/A
Forward P/E N/A
EPS (TTM) $-7.98
PEG Ratio N/A
Dividend Yield N/A
Revenue (TTM) $2.2B
Profit Margin -141.4%
52-WEEK RANGE
52-Week Low $22.28
52-Week High $202.67
Current Price $198.88
Bear Target $45.0
Bull Target $170.0
● Now $198.88 ● Target $119.56
TRADING DATA
Avg Volume 16.9M
YTD Return +544.5%
Analyst Count 18
Consensus Hold
Upside to Target -39.9%
Last Updated 2026-09-28

ANALYST SUMMARY

Moderna, Inc. (MRNA) is currently trading at $198.88 with a Wall Street consensus price target of $119.56, which is 39.9% below the current price over the next 12 months. 18 analysts currently cover MRNA, with a consensus rating of Hold - 22% of analysts rate the stock a Buy or Strong Buy. The most bullish analyst has a price target of $170.0, while the most cautious has a target of $45.0.

MRNA operates in the Healthcare sector with a market capitalisation of $79B. The stock is up 544.5% year-to-date and is currently trading near the upper end of its 52-week range of $22.28 – $202.67.

SIMILAR STOCKS

Other Healthcare stocks with comparable size and valuation.

RECENT ANALYST CALLS

Upgrade/downgrade history for MRNA, with each firm's 90-day track record across all stocks we track. See full firm rankings →

Rothschild & Co ↓ Downgrade
Neutral → Sell 2026-09-03 Building track record
Argus Research ↑ Upgrade
Hold → Buy 2026-08-28 Building track record
Wolfe Research ↑ Upgrade
Underperform → Peer Perform 2026-08-25 Building track record
Barclays - Reiterated
Equal-Weight → Equal-Weight 2026-08-24 Building track record
JP Morgan - Reiterated
Underweight → Underweight 2026-08-21 43% win rate (7 calls)
Goldman Sachs - Reiterated
Neutral → Neutral 2026-08-20 Building track record
UBS - Reiterated
Neutral → Neutral 2026-08-20 33% win rate (6 calls)
Morgan Stanley - Reiterated
Equal-Weight → Equal-Weight 2026-08-20 Building track record
HISTORICAL SNAPSHOT

Point-in-time data from StockUpside's daily snapshots. Tracks price, analyst target, upside %, consensus, and analyst count.

Loading…
ANALYST CONVICTION SCORE
41
out of 100
Coverage depth
22/30
Consensus clarity
17/30
Vote unanimity
0/25
Rating stability
2/15

Measures analyst agreement, not fundamental quality. A high score means analysts broadly agree on this call - not that the stock will go up.

See 4,000+ stocks ranked by analyst upside

StockUpside.io tracks analyst consensus price targets across thousands of US-listed stocks, updated every day. The full ranked list is available with a Pro subscription.

View Full Rankings →